Traitement des patients diabétiques de type 2 à risque cardio-rénal : ESC versus ADA-EASD.

Scheen, André; Paquot, Nicolas

Request a copy

Article (Scientific journals)

Traitement des patients diabétiques de type 2 à risque cardio-rénal : ESC versus ADA-EASD.

Scheen, André; Paquot, Nicolas

2020 • In Revue Médicale Suisse, 16 (703), p. 1478-1482

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/250439

PubMed
32852167

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2020 RMS Protection cardiorénale avec les inhibiteurs des SGLT2.pdf

Publisher postprint (181.16 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Glucagon-like peptide-1 receptor agonists; SGLT2 inhibitors; cardiovascular protection; renalprotection; ESC; ADA-EASD; type 2 diabetes

Abstract :

[en] Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors (gliflozins), which demonstrated a cardiovascular and renal protection, have profoundly changed the management of patients with type 2 diabetes who are at cardiovascular risk. Nowadays, these antidiabetic medications occupy a preferred position, independently of glucose control. This has been emphasized in the last guidelines of the European Society of Cardiology (ESC) and the joint consensus by the American Diabetes Association and the European Association for the Study of Diabetes (ADA-EASD), both published in 2020. Nevertheless, there are some discrepancies between the two points of view, especially concerning the definition of the patient at cardiovascular risk in primary prevention and the first-choice place still to be reserved to metformin in these patients.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Traitement des patients diabétiques de type 2 à risque cardio-rénal : ESC versus ADA-EASD.

Alternative titles :

[en] Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD

Publication date :

2020

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

703

Pages :

1478-1482

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 August 2020

Statistics

Number of views

120 (5 by ULiège)

Number of downloads

6 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ. Vers un nouveau paradigme dans le traitement du diabète de type 2. Rev Med Suisse 2019;15:1423-4.
*Scheen AJ, Paquot N. Une révolution dans le traitement du diabète de type 2: des antidiabétiques dotés d’une protection cardio-rénale indépendamment du contrôle glycémique ! Rev Med Liege 2020;75:392-8.
Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2018;41:14-31.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461-98.
American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S111-S34.
Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019;139:2022-31.
Scheen AJ, Paquot N. Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire ? Rev Med Suisse 2018;14:1460-5.
Scheen AJ. Combinaison « inhibiteur des SGLT2-agoniste des récepteurs du GLP-1» pour traiter le diabète de type 2. Rev Med Suisse 2019; 15:1436-41.
Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;epub ahead of print.
**Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323.
**Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:221-8.
Scheen AJ. Editorial: De la différence entre consensus d’experts et recommandations. Rev Med Suisse 2020;16:1475-6.
Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2. Rev Med Liege 2020;75:233-9.
Scheen AJ. Series: Implications of the recent CVOTs in Type 2 Diabetes: Impact on guidelines: the endocrinologist point of view. Diabetes Res Clin Pract 2020;159:107726.
Chilton RJ, Gallegos KM, Silva-Cardoso J, et al. The evolving role of the cardiologist in the management of type 2 diabetes. Curr Diab Rep 2018;18:144.
Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 2019;34:208-30.
Scheen AJ. Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin? Diabetes Res Clin Pract 2019;147:169-71.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.
Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 2018;138:1904-7.
Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation 2020;141:407-10.
Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. Diabetes Care 2019;42:e42-e4.
*Scheen AJ. Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes Metab 2020;46:181-5.
*Scheen AJ. Traiter le patient diabétique de type 2 à risque: analyse critique des recommandations de l’European Society of Cardiology (ESC). Med Mal Metab 2020; 14 (n° 5): sous presse.
UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS Group). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
Griffin SJ, Leaver JKIrving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017;60:1620-9.
Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract 2020;160:108001.
Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia 2017;60:1630-8.
Marshall SM. 60 years of metformin use: a glance at the past and a look to the future. Diabetologia 2017;60:1561-5.
Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract 2020;159:107946.
Darmon P, Bauduceau B, Bordier L, et al. Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l’hyperglycémie du patient diabétique de type 2 – 2019. Med Mal Metab 2019;13:711-32.